Invention Grant
- Patent Title: Combination dosage form of a mu opioid receptor antagonist and an opioid agent
-
Application No.: US15798647Application Date: 2017-10-31
-
Publication No.: US10369142B2Publication Date: 2019-08-06
- Inventor: Shaoling Li , Manshiu Leung , Hao Zhang , Venkat R. Thalladi , Yun Mo
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Florence Jovic
- Main IPC: A61K31/46
- IPC: A61K31/46 ; A61K31/439 ; A61K31/485 ; A61K9/24 ; A61K9/28
Abstract:
The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.
Public/Granted literature
- US20180050028A1 COMBINATION DOSAGE FORM OF A MU OPIOID RECEPTOR ANTAGONIST AND AN OPIOID AGENT Public/Granted day:2018-02-22
Information query
